News
Celltrient™ Cellular Energy Products Featuring Tru Niagen® Launch in US
Nestlé Health Science launches Celltrient™ products to help fight key drivers of cell aging featuring ChromaDex's flagship ingredient Tru Niagen® LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) today announced its flagship ingredient, Tru Niagen®, is...
New Preclinical Study Finds Nicotinamide Riboside May Improve Immune Cell Function
A study in Nature Immunology found that nicotinamide riboside (NR) improved the anti-cancer function of tumor infiltrating immune T-cells in mice LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) today highlighted a new study from Nature Immunology that found nicotinamide...
ChromaDex Announces Study Results Showing Nutritional Protocol Including Nicotinamide Riboside Plus Standard of Care Reduces Recovery Time in COVID-19 Patients by Nearly 30%
Phase 2 study finds addition of nutritional protocol to standard of care reduces recovery time to 6.6 days from 9.3 in mild-to-moderate COVID-19 patients LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) today announced that results from the study "Combined metabolic...
New Preclinical Study Finds Niagen® Prevents Light-Induced Retinal Damage in Mice
Preclinical study at Emory University explores relationship between cellular NAD+ and retinal damage LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) today announced new preclinical research published in Investigative Ophthalmology & Visual Science finding Niagen®...
New Pilot Study Indicates Niagen® May Reduce Inflammatory Cytokines in Stage D Heart Failure Patients
Niagen® (patented nicotinamide riboside) may reduce production of inflammatory cytokines in pilot study of Stage D heart failure patients LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) today announced the 11th published human trial on its patented NAD-boosting...
ChromaDex Corporation Reports Second Quarter 2020 Financial Results
Second Quarter 2020 Highlights vs. Second Quarter 2019 Strong growth in net sales to $15.3 million, higher gross margins, and significantly improved marketing efficiency year-over-year. Tru Niagen net sales of $11.7 million, a 34% increase year-over-year. Net loss was...
ChromaDex to Report Second Quarter 2020 Financial Results on Thursday, August 6, 2020
LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Thurs., August 6, 2020 at 4:30 p.m. ET to discuss its financial results for the second quarter ended Jun. 30, 2020. The financial results will be reported in a press release...
New Preclinical Study Finds Niagen® Corrects Social Deficits in Mouse Model of Autism
First-of-its-kind preclinical study shows that Niagen® (nicotinamide riboside) resolves social deficits and anxiety-like behaviors in male mice LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) today announced the results of a new preclinical study published in Nature...
ChromaDex External Research Program (CERP™) Achieves 200th Material Transfer Agreement for Niagen® (Nicotinamide Riboside) Research
ChromaDex R&D program continues to pioneer NAD+ and Niagen® research and inks over 200 external research collaborations LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) today announced the Company has signed its 200th material transfer agreement (MTA) through its...
ChromaDex Announces New Study Results Highlighting Promising Anti-Viral Effects of Niagen® in Coronavirus Cell Model
Dr. Charles Brenner and a team of scientists from three US universities find that Niagen® decreases Coronavirus replication in animal cells LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) today announced the latest preclinical findings indicating Niagen®...